In HCC cells, it was demonstrated that the combination of sorafenib with VPA synergistically inhibited HCC cell viability through the induction of intrinsic apoptosis involving p21, BAX, cleaved caspase 9, cleaved caspase 3 and cleaved PARP and the down-regulation of BCL-xL and SURVIVIN [33,126]. The gene discussed is CASP9; the disease is hepatocellular carcinoma.